|
SPORE in Pancreatic Cancer
|
3P20CA101936-05S1
|
$521,256
|
$172,014
|
ABBRUZZESE, JAMES
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
A novel ellipticine analog as a therapeutic candidate for acute myeloid leukemia
|
1R43CA141915-01
|
$153,770
|
$153,770
|
Agarwal, Mukesh
|
CLEVELAND LEUKEMIA THERAPEUTICS, LLC
|
|
Prostate Cancer Prevention and Treatment by Silibinin
|
2R01CA102514-06
|
$334,007
|
$167,004
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
4R44CA124032-02
|
$1,473,388
|
$1,473,388
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
Bone-seeking proteasome inhibitors for myeloma
|
5K01CA113468-05
|
$153,226
|
$153,226
|
AGYIN, JOSEPH
|
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
|
|
The CCNY/MSKCC Partnership for Research, Training and Outreach
|
3U54CA137788-02S1
|
$200,000
|
$24,000
|
Ahles, Tim
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
The CCNY/MSKCC Partnership for Research, Training and Outreach
|
5U54CA137788-02
|
$1,404,429
|
$168,531
|
Ahles, Tim
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Participation in the Eastern Cooperative Oncology Group
|
5U10CA107868-06
|
$238,147
|
$238,147
|
AISNER, JOSEPH
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
Molecular Biomarkers as Classifiers to Individualize Therapy of Esophagus Cancer
|
1R21CA129906-01A2
|
$183,352
|
$60,506
|
Ajani, Jaffer
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Molecular Markers of Response to Chemoradiation in Localized Esophageal Cancer
|
5R21CA127672-02
|
$138,600
|
$138,600
|
Ajani, Jaffer
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Biodegradable Polymeric Nanosphere Drug Delivery System For Cancer Chemotherapy
|
5SC2CA138179-02
|
|
$0
|
AKALA, EMMANUEL
|
HOWARD UNIVERSITY
|
|
Prevention of Metastatic Cancer Using a Novel Vitamin E Analog
|
5R01CA120552-04
|
$241,727
|
$120,864
|
AKPORIAYE, EMMANUEL
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
Molecular Interaction Maps and Analysis of Bioregulatory Networks
|
ZIA BC 010562
|
$79,172
|
$3,959
|
Aladjem, Mirit
|
CCR (NCI)
|
|
Clinical Academic Oncologist Training Program
|
5K12CA087718-10
|
|
$0
|
Albertini, Mark
|
UNIVERSITY OF WISCONSIN MADISON
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
2P30CA023074-31
|
$4,161,907
|
$624,286
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-31S1
|
$105,806
|
$15,871
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
Novel Targeted Therapeutics for Cental Nervous System Malignancies
|
5R01CA112519-04
|
$335,460
|
$83,865
|
Ali-Osman, Francis
|
DUKE UNIVERSITY
|
|
Protein Kinase C and GSTP1 interactions in glioma drug resistance
|
5R01CA127872-02
|
$323,700
|
$323,700
|
Ali-Osman, Francis
|
DUKE UNIVERSITY
|
|
Cdk-2 Independent role of cyclin E in Cell survival
|
1R01CA127264-01A2
|
$325,302
|
$325,302
|
Almasan, Alexandru
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
Rational Design and Clinical Development of Shepherdin: A Novel Anti-Cancer Agent
|
1R01CA118005-01A2
|
$340,386
|
$340,386
|
Altieri, Dario
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
Therapeutic approaches that target cancer cell metabolism
|
5K23CA120862-02
|
$137,295
|
$137,295
|
AMARAVADI, RAVI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Autophagy inhibition as a therapeutic strategy for glioblastoma mutliforme
|
5R21CA133898-02
|
$356,164
|
$356,164
|
AMARAVADI, RAVI
|
UNIVERSITY OF PENNSYLVANIA
|
|
SPORE in Lymphoma
|
3P50CA096888-05S2
|
$304,005
|
$76,001
|
AMBINDER, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
|
Antioxidant supplements, genetics, and chemotherapy outcomes
|
5R01CA116395-04
|
$615,542
|
$615,542
|
Ambrosone, Christine
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Contributions of sleep/rhythms/fatigue to "chemobrain"
|
5R01CA112035-05
|
$391,550
|
$391,550
|
Ancoli-Israel, Sonia
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
RECEPTOR-TARGETED COPPER RADIOPHARMACEUTICALS FOR CANCER IMAGING AND THERAPY
|
2R01CA064475-14A2
|
$292,410
|
$292,410
|
ANDERSON, CAROLYN
|
WASHINGTON UNIVERSITY
|
|
SPORE in Myeloma
|
5P50CA100707-07
|
$2,300,000
|
$1,380,000
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INSTITUTE
|
|
Children's Oncology Group Statistics and Data Center Grant
|
5U10CA098413-07
|
$5,725,544
|
$5,725,544
|
ANDERSON, JAMES
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Mechanistic Targeting of Lung Cancer
|
ZIA BC 005399
|
$508,475
|
$254,238
|
Anderson, Lucy
|
CCR (NCI)
|
|
THE THERAPY OF AML
|
5P01CA055164-17
|
$2,440,745
|
$1,220,373
|
ANDREEFF, MICHAEL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Extension of Radiotherapy Research
|
3P01CA006294-44S1
|
$300,000
|
$300,000
|
ANG, K
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Biologic Therapy for B-cell non-Hodgkin's Lymphoma
|
5R01CA092104-06
|
$258,741
|
$258,741
|
ANSELL, STEPHEN
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
Biosynthesis of Taxol Precursors in Transgenic Moss
|
1R15CA139416-01
|
$218,250
|
$218,250
|
Anterola, Aldwin
|
SOUTHERN ILLINOIS UNIVERSITY CARBONDALE
|
|
Mechanisms of GVHD
|
9P01CA142106-06A1
|
$1,953,263
|
$976,632
|
ANTIN, JOSEPH
|
DANA-FARBER CANCER INSTITUTE
|
|
Development of Immunotherapeutic Strategies in the Treatment of Lung Cancer
|
5K24CA128953-02
|
$164,476
|
$164,476
|
ANTONIA, SCOTT
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
GENETIC PREDICTORS OF LEUKEMIA THERAPY RESPONSE
|
5R01CA108862-05
|
$256,197
|
$256,197
|
Aplenc, Richard
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
SPORE in Breast Cancer
|
5P50CA098131-07
|
$2,300,000
|
$575,000
|
ARTEAGA, CARLOS
|
VANDERBILT UNIVERSITY
|
|
Structural Basis of Multidrug resistance in Cancer
|
5K01CA113486-05
|
$155,422
|
$155,422
|
ASOJO, OLUWATOYIN
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
DF/HCC Kidney Cancer SPORE
|
2P50CA101942-06A1
|
$2,300,000
|
$276,000
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Southeast Cancer Control Consortium, Inc
|
5U10CA045808-23
|
$2,304,698
|
$967,973
|
ATKINS, JAMES
|
SOUTHEAST CANCER CONTROL CONSORTIUM
|
|
Eastern Cooperative Oncology Group
|
5U10CA080775-11
|
$130,866
|
$130,866
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Defining clinical efficacy and markers predicting response to bortezomib in AML
|
5K23CA118419-03
|
$142,560
|
$142,560
|
Attar, Eyal
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
New Cancer Vaccine Technology Based on DRibbles Produced by Tumor Cells
|
2R44CA121612-02A1
|
$760,163
|
$250,854
|
Aung, Sandra
|
UBIVAC, LLC
|
|
Eastern Cooperative Oncology Group Studies
|
5U10CA014548-35
|
$417,370
|
$417,370
|
AVERBOOK, BRUCE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Purification of a Novel Antibody Against Solid Organ Cancer Stem Cells
|
ZIA BC 010997
|
$217,176
|
$217,176
|
Avital, Itzhak
|
CCR (NCI)
|
|
Mechanism of Drug Transport in Lung Cancer Cells
|
5R01CA077495-11
|
$243,821
|
$60,955
|
Awasthi, Sanjay
|
UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
|
|
Early Clinical Testing for Melanin Targeting Radio-therapeutic agent in melanoma
|
1R44CA141936-01
|
$223,985
|
$223,985
|
Babich, John
|
MOLECULAR INSIGHT PHARMACEUTICALS, INC.
|
|
ENGINEERED INTELLIGENT MICELLE FOR TUMOR pH TARGETING
|
2R01CA101850-05A1
|
$271,181
|
$271,181
|
Bae, You
|
UNIVERSITY OF UTAH
|
|
Micelle surface engineering for active targeting by acidic tumor extracellular pH
|
5R01CA122356-04
|
$257,668
|
$257,668
|
Bae, You
|
UNIVERSITY OF UTAH
|
|
San Juan Minority - Based Community Clinical Oncology Program
|
5U10CA052667-19
|
$687,330
|
$309,299
|
BAEZ, LUIS
|
SAN JUAN HEALTH DEPARTMENT
|
Total relevant funding to Chemotherapy for this search: $528,665,822
|